Therefore, therapeutic strategies to deplete arginine are considered promising and have been shown to be particularly effective in argininosuccinate synthetase 1 (ASS1)‐deficient cancers, as ASS1 is the rate‐limiting enzyme of arginine synthesis [99]. Here, ASS1 is linked to cancer.